keyword
MENU ▼
Read by QxMD icon Read
search

DMARD

keyword
https://www.readbyqxmd.com/read/28644744/add-on-iguratimod-as-a-therapeutic-strategy-to-achieve-remission-in-patients-with-rheumatoid-arthritis-inadequately-responding-to-biological-dmards-a-retrospective-study
#1
Ayaka Yoshikawa, Shuzo Yoshida, Yuko Kimura, Nao Tokai, Yohei Fujiki, Takuya Kotani, Yoko Matsumura, Tohru Takeuchi, Shigeki Makino
OBJECTIVES: In this study, iguratimod (IGU) was added to rheumatoid arthritis (RA) patients inadequately responding to 24-week or longer treatment with biological disease-modifying antirheumatic drug (bDMARDs), its effectiveness was assessed, and factors contributing to remission were evaluated. METHODS: RA patients who fulfilled the following criteria were included: (i) ≥ 24-week of bDMARDs; (ii) 2.6 < disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) < 5...
June 23, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28638693/management-of-the-temporomandibular-joint-in-inflammatory-arthritis-involvement-of-surgical-procedures
#2
REVIEW
Rory C O'Connor, Fiona Fawthrop, Rami Salha, Andrew J Sidebottom
Many conditions may affect the temporomandibular joint (TMJ), but its incidence in individual joint diseases is low. However, inflammatory arthropathies, particularly rheumatoid and psoriatic arthritis and ankylosing spondylitis, appear to have a propensity for affecting the joint. Symptoms include pain, restriction in mouth opening, locking, and noises, which together can lead to significant impairment. Jaw rest, a soft diet, a bite splint, and medical therapy, including disease-modifying antirheumatic drugs (DMARDs) and simple analgesia, are the bedrock of initial treatment and will improve most symptoms in most patients...
June 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28634699/cost-effective-analysis-of-disease-modifying-anti-rheumatic-drugs-in-rheumatoid-arthritis
#3
Ashit Syngle, Sudeep Kaur, Inderjeet Verma, Tanya Syngle, Vijaita Syngle
The main objective of the study was to perform the pharmacoeconomic analysis of synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients. A prospective, observational study was conducted in 98 rheumatoid arthritis (RA) patients meeting 2010 Rheumatoid Arthritis Classification Criteria. Treatment-naive RA patients were initiated on synthetic disease-modifying anti-rheumatic drugs (DMARD/s) and followed up for 3 months. Average cost-effectiveness analysis was done by taking Health Assessment Questionnaire Disability Index (HAQ-DI) score as a measure of effectiveness...
June 21, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28634103/undetectable-mannose-binding-lectin-and-corticosteroids-increase-serious-infection-risk-in-rheumatoid-arthritis
#4
Graeme J Carroll, Krista Makin, Maxine Garnsey, Max Bulsara, Bronwyn V Carroll, Shona M Curtin, Erin M Allan, Andrew McLean-Tooke, Christine Bundell, Monica L Kemp, Pooja Deshpande, Dana Ihdayhid, Sophie Coleman, Tracie Easter, James Triplett, Timothy Disteldorf, C Helen Marsden, Michaela Lucas
BACKGROUND: Infection is the leading cause of death in rheumatoid arthritis (RA). Corticosteroid (CS) use is a known and important risk factor for serious infections (SIs). Mannose binding lectin (MBL) is a genetically determined component of the innate immune system implicated in neonatal infections. OBJECTIVE: Our aim was to determine whether MBL deficiency is a risk factor for SIs in RA and to compare it with CS use and also synthetic and biologic disease-modifying antirheumatic drug (DMARD) therapy...
June 17, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28631046/adherence-of-rheumatoid-arthritis-patients-to-biologic-disease-modifying-antirheumatic-drugs-a-cross-sectional-study
#5
Natalia Mena-Vazquez, Sara Manrique-Arija, Lucía Yunquera-Romero, Inmaculada Ureña-Garnica, Marta Rojas-Gimenez, Carla Domic, Francisco Gabriel Jimenez-Nuñez, Antonio Fernandez-Nebro
The aims of this study were to evaluate adherence of rheumatoid arthritis (RA) patients to biological disease-modifying antirheumatic drugs (bDMARDs), identify potential risk factors, and analyze the discriminative ability of the Morisky-Green test (MGT) to detect bDMARD nonadherence. One hundred and seventy-eight adult RA patients treated with bDMARDs were included. Adherence was measured using the medication possession ratio (MPR) of the previous 6 months. An MPR >80% was considered good adherence. Patient demographics, clinical characteristics, and MGT scores were assessed through a standardized clinical interview at the cross-sectional date...
June 19, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28630629/the-cedar-study-a-longitudinal-study-of-the-clinical-effects-of-conventional-dmards-and-biologic-dmards-in-australian-rheumatology-practice
#6
Lynden Roberts, Kathleen Tymms, Julien de Jager, Geoffrey Littlejohn, Hedley Griffiths, Dave Nicholls, Paul Bird, Jennifer Young, Julie Hill, Jane Zochling
OBJECTIVES: To observe the choices of conventional disease modifying antirheumatic drugs (cDMARDs) and biologic DMARDs (bDMARDs) in the management of rheumatoid arthritis (RA) in Australian routine clinical practice, to assess treatment survival and determine the effect of cDMARDs/bDMARDs on disease activity. METHODS: Routinely collected, deidentified clinical data was sourced from 20 Australian rheumatology practices. RA patients aged ≥18 years, who had received cDMARDs/bDMARDs and a recorded subsequent visit, were included...
2017: International Journal of Rheumatology
https://www.readbyqxmd.com/read/28628468/dapsa-das28-and-mda-predict-long-term-treatment-regime-in-psoriatic-arthritis-the-swedish-early-psoriatic-arthritis-cohort
#7
Ulla Lindqvist, Mona-Lisa Wernroth, Tomas Husmark, Per Larsson, Mats Geijer, Annika Teleman, Elke Theander, Gerd-Marie Alenius
OBJECTIVES: To describe treatment patterns in the Swedish early psoriatic arthritis cohort (SwePsA) of the mono-/oligo-arthritic (M/O) and polyarthritis (P) and identify early predictive factors for treatment with disease-modifying anti-rheumatic (DMARD), non-steroidal anti-inflammatory drugs (NSAID), and tumour necrosis factor inhibition (TNFi) after 5 years. METHODS: Data for 198 M/O and P PsA were obtained within the programme for SwePsA. Multinomial and binary logistic regression analyses were used to assess the association between early predictive factors and treatment after 5 years adjusted for age at inclusion...
June 16, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28615732/managing-rheumatic-and-musculoskeletal-diseases-past-present-and-future
#8
REVIEW
Gerd R Burmester, Johannes W J Bijlsma, Maurizio Cutolo, Iain B McInnes
Progress in rheumatology has been remarkable in the past 70 years, favourably affecting quality of life for people with rheumatic and musculoskeletal diseases. Therapeutics have advanced considerably in this period, from early developments such as the introduction of glucocorticoid therapy to the general use of methotrexate and other disease-modifying agents, followed by the advent of biologic DMARDs and, most recently, small-molecule signalling inhibitors. Novel strategies for the use of such agents have also transformed outcomes, as have multidisciplinary nonpharmacological approaches to the management of rheumatic musculoskeletal disease including surgery, physical therapy and occupational therapy...
July 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28615036/predictors-of-the-response-to-etanercept-in-patients-with-juvenile-idiopathic-arthritis-without-systemic-manifestations-within-12-months-results-of-an-open-label-prospective-study-conducted-at-the-national-scientific-and-practical-center-of-children-s-health
#9
Ekaterina I Alexeeva, Leyla S Namazova-Baranova, Tatyana M Bzarova, Saniya I Valieva, Rina V Denisova, Tatyana V Sleptsova, Kseniya B Isaeva, Alexandra M Chomahidze, Nikolay I Taibulatov, Anna N Fetisova, Anna V Karaseva, Alexandr A Baranov
BACKGROUND: The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations. METHODS: A total of 197 juvenile patients were enrolled in this study. Response to therapy was assessed using the ACRPedi 30/50/70/90 criteria, the Wallace criteria, and the Juvenile Arthritis Disease Activity Score 71 (JADAS-71)...
June 14, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28610614/drug-safety-analyses-in-a-rheumatoid-arthritis-registry-application-of-different-approaches-regarding-timing-of-exposure-and-confounder-measurement
#10
Daniel H Solomon, Nancy A Shadick, Michael E Weinblatt, Agnes Zak, Michelle Frits, Jessica M Franklin
BACKGROUND: Patient registry data serves an increasing role in drug safety and comparative effectiveness research, but registry databases often do not contain confounder information measured at the same time that treatments begin. This study evaluated a set of approaches for estimating confounder values at treatment initiation using actual data from a rheumatoid arthritis (RA) registry to examine the risk of infection associated with different biologic DMARDs (bDMARDs). METHODS: We examined the risk of infection associated with starting a TNF inhibitor (TNFi) versus any of the other non-TNFi bDMARDs...
June 13, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28609439/interventions-for-treating-patients-with-chikungunya-virus-infection-related-rheumatic-and-musculoskeletal-disorders-a-systematic-review
#11
Arturo Martí-Carvajal, Pilar Ramon-Pardo, Emilie Javelle, Fabrice Simon, Sylvain Aldighieri, Hacsi Horvath, Julia Rodriguez-Abreu, Ludovic Reveiz
BACKGROUND: Chikungunya virus infection (CHIKV) is caused by a mosquito-borne alphavirus. CHIKV causes high fever and painful rheumatic disorders that may persist for years. Because little is known about interventions for treating CHIKV-related illness, we conducted a systematic review. METHODS: We used Cochrane methods. We searched PubMed, EMBASE, Cochrane Library, LILACS and other sources from the earliest records to March 2016. We had no language restrictions...
2017: PloS One
https://www.readbyqxmd.com/read/28608166/abatacept-a-review-in-rheumatoid-arthritis
#12
Hannah A Blair, Emma D Deeks
The biological DMARD (bDMARD) abatacept (Orencia(®)), a recombinant fusion protein, selectively modulates a co-stimulatory signal necessary for T-cell activation. In the EU, abatacept is approved for use in patients with highly active and progressive rheumatoid arthritis (RA) not previously treated with methotrexate. Abatacept is also approved for the treatment of moderate to severe active RA in patients with an inadequate response to previous therapy with at least one conventional DMARD (cDMARD), including methotrexate or a TNF inhibitor...
June 12, 2017: Drugs
https://www.readbyqxmd.com/read/28601838/are-dietary-vitamin-d-omega-3-fatty-acids-and-folate-associated-with-treatment-results-in-patients-with-early-rheumatoid-arthritis-data-from-a-swedish-population-based-prospective-study
#13
Cecilia Lourdudoss, Alicja Wolk, Lena Nise, Lars Alfredsson, Ronald van Vollenhoven
BACKGROUND: Dietary intake of vitamin D and omega-3 fatty acids (FA) may be associated with superior response to antirheumatic treatments. In addition, dietary folate intake may be associated with worse response to methotrexate (MTX). The aim of this study was to investigate the association between dietary vitamin D, omega-3 FA, folate and treatment results of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). METHODS: This prospective study was based on data from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study, and included 727 patients with early RA from 10 hospitals in Sweden...
June 10, 2017: BMJ Open
https://www.readbyqxmd.com/read/28601249/the-2010-acr-eular-criteria-are-not-sufficiently-accurate-in-the-early-identification-of-autoantibody-negative-rheumatoid-arthritis-results-from-the-leiden-eac-and-espoir-cohorts
#14
Debbie M Boeters, Cécile Gaujoux-Viala, Arnaud Constantin, Annette H M van der Helm-van Mil
OBJECTIVES: The 2010 ACR/EULAR criteria were derived to classify rheumatoid arthritis (RA) earlier in time. Previous studies indeed observed that the 2010 criteria were fulfilled earlier than the 1987 criteria. This study determined whether the 2010 criteria perform equally in early classification of autoantibody-positive and autoantibody-negative RA. METHODS: From the total Leiden-EAC (n = 3448) and ESPOIR (n = 813) RA patients who fulfilled the 1987 RA criteria at 1 year but not at presentation were selected (n = 463 and n = 53, respectively), as these patients were classified with delay with the 1987 criteria...
April 29, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28598787/severe-adverse-drug-reactions-to-biological-disease-modifying-anti-rheumatic-drugs-in-elderly-patients-with-rheumatoid-arthritis-in-clinical-practice
#15
Leticia Leon, Alejandro Gomez, Cristina Vadillo, Esperanza Pato, Luis Rodriguez-Rodriguez, Juan Angel Jover, Lydia Abasolo
OBJECTIVES: Biological DMARDs are widely used in the treatment of rheumatoid arthritis (RA) but their relationship with adverse drug reaction (ADR) is important. RA is now known to increase in incidence and prevalence with age. Our objective was to assess the incidence of severe ADR in the long term, compare safety between the different bDMARDs and identify other possible risk factors for severe ADR in elderly RA patients. METHODS: A 14-year retrospective longitudinal study was performed...
June 6, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28598786/prevalence-and-risk-factors-for-liver-fibrosis-detected-by-transient-elastography-or-shear-wave-elastography-in-inflammatory-arthritis-a-systematic-review
#16
Azin Rouhi, Glen Hazlewood, Abdel-Aziz Shaheen, Mark G Swain, Claire E H Barber
OBJECTIVES: Emerging technologies for monitoring subclinical liver fibrosis include transient elastography (TE) and shear wave elastography (SWE). A systematic review was conducted to assess the prevalence and report on predictors of liver fibrosis as detected by these technologies in inflammatory arthritis (IA) patients, including rheumatoid arthritis, spondyloarthritis and juvenile idiopathic arthritis. METHODS: MEDLINE, EMBASE and Web of Science were searched from inception to 06/27/2016 using search terms for IA or DMARDs and TE/SWE...
June 5, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28598774/what-could-we-learn-from-the-sub-analysis-of-a-single-nation-cohort-in-a-worldwide-study-lessons-from-the-results-observed-in-the-italian-cohort-of-the-go-more-trial
#17
Roberto Giacomelli, Piero Ruscitti, Stefano Bombardieri, Giovanna Cuomo, Salvatore De Vita, Mauro Galeazzi, Monica Mecchia
OBJECTIVES: GO-MORE Trial investigated the use of Golimumab (GLM) in 3280 rheumatoid arthritis (RA) patients worldwide. At present, the burden of arthritis is greater in poorer countries than in developed countries due to socioeconomic disparities, thus suggesting the usefulness of subgroup investigations. We aimed to evaluate GLM as add-on therapy for RA patients in the Italian cohort of GO-MORE trial and compared the clinical characteristics between Italian patients and the enrolled patients worldwide...
June 6, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28598681/soluble-cd206-plasma-levels-in-rheumatoid-arthritis-reflect-decrease-in-disease-activity
#18
Line Dam Heftdal, Kristian Stengaard-Pedersen, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland, Kim Hørslev-Petersen, Peter Junker, Mikkel Østergaard, Malene Hvid, Bent Deleuran, Holger Jon Møller, Stinne Ravn Greisen
Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and infiltration by activated macrophages. TNFα is a central mediator in this process. The mannose receptor, CD206, is a scavenger receptor expressed by M2A-macrophages and dendritic cells. It is involved in collagen internalization and degradation. The soluble form has been suggested as a biomarker of M2A-macrophage activation. The aim of this study was to investigate sCD206 plasma levels in early RA patients initiating anti-TNFα treatment...
June 9, 2017: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/28597609/transaminase-levels-and-hepatic-events-during-tocilizumab-treatment-pooled-analysis-of-long-term-clinical-trial-safety-data-in-rheumatoid-arthritis
#19
Mark C Genovese, Joel M Kremer, Ronald F van Vollenhoven, Rieke Alten, Juan Jose Scali, Ariella Kelman, Sophie Dimonaco, Laura Brockwell
OBJECTIVE: Investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long-term tocilizumab treatment for rheumatoid arthritis (RA) in clinical trials. METHODS: Data were pooled from patients who received intravenous tocilizumab (4, 8, or 10 mg/kg ± disease-modifying antirheumatic drugs [DMARDs]) in phase 3 or 4 clinical trials, long-term extensions, and a pharmacology study. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured routinely in these trials...
June 8, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28597306/maintenance-of-remission-with-combination-etanercept-dmard-therapy-versus-dmards-alone-in-active-rheumatoid-arthritis-results-of-an-international-treat-to-target-study-conducted-in-regions-with-limited-biologic-access
#20
Karel Pavelka, Nurullah Akkoç, Mustafa Al-Maini, Cristiano A F Zerbini, Dmitry E Karateev, Evgeny L Nasonov, Mahboob U Rahman, Ronald Pedersen, Andrew Dinh, Qi Shen, Radu Vasilescu, Sameer Kotak, Ehab Mahgoub, Bonnie Vlahos
In this transglobal, randomized, double-blind, placebo-controlled, treat-to-target study, the maintenance of efficacy was compared between biologic-and biologic-free-disease-modifying antirheumatic drug (DMARD) combination regimens after low disease activity (LDA) was achieved with biologic DMARD induction therapy. Patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy received open-label etanercept 50 mg subcutaneously once weekly plus methotrexate with or without other conventional synthetic (cs) DMARDs for 24 weeks...
June 9, 2017: Rheumatology International
keyword
keyword
61414
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"